Home > Boards > US OTC > Medical - Equipment >

Positron Corporation (POSC)

Add POSC Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/3/2020 9:55:08 AM - Followers: 167 - Board type: Free - Posts Today: 0


Symbol: OTC: POSC

Positron is a nuclear medicine healthcare company specializing in the business of cardiac Positron Emission Tomography (PET). Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease (CAD), a leading cause of death in the United States. Positron’s products and services empower healthcare providers to more accurately diagnose CAD and improve patient outcomes while practicing cost effective medicine.

Positron, a pioneer in nuclear cardiology for over 30 years, is establishing a unique position by vertically integrating the fragmented and limited supply environment that exists in the cardiac PET marketplace today. Positron’s approach is to provide nuclear cardiologists an end-to-end solution by offering award-winning imaging technology, clinical services, imaging agents and innovative financing packages conveniently from a single source.  Positron's business approach will bring substantial advantages in accelerating the adoption of this superior modality and growth of the nuclear cardiology industry.

Positron Corporation is a publicly listed company. Shares of common stock of Positron Corporation are currently trading on the National Association of Securities Dealers, Inc.'s under the symbol POSC.

Key Business Components 
PET Imaging System and Services
The Attrius®, dedicated PET imaging system, is optimized for cardiology. Positron's Attrius provides customers with state-of-the-art imaging technology for the diagnosis, treatment and prevention of cardiovascular disease. The Attrius is the only dedicated PET scanner in the world and was awarded Frost & Sullivan's Most Innovative Medical Device of the Year award as "the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology."  Positron complements its technology by offering comprehensive world-class clinical, technical and service support through their PosiStar™ customer care plan.

Financing Solutions
Positron provides customers with a variety of financing solutions for its full solutions model designed to minimize any barriers to entry, thus accelerating the expansion of cardiac PET and further securing Positron's current and future position in the market.

Market Opportunities
Nuclear medicine helps in the diagnosis, management and prevention of patients with cardiovascular disease (CVD). Radiopharmaceuticals are injected into a patient to provide the most accurate, non-invasive test for identifying narrowed coronary arteries, mild cholesterol build-up or diffuse coronary vascular disease; conditions that are responsible for almost all heart attacks. Cardiovascular disease is the leading cause of death in the United States and constitutes 17% of overall national health expenditures (Forecasting the Future of Cardiovascular Disease in the United States, American Heart Association, 2011).  Direct CVD costs are projected to increase from $273 billion in 2010 to $818 billion in 2030, and indirect costs (due to lost productivity) will rise from $172 billion in 2010 to $276 billion in 2030.
Positron Emission Tomography (PET)
PET is a more advanced and accurate technology. In cardiac perfusion imaging, PET scanners, in particular Positron's Attrius, have superior sensitivity and specificity compared to that of SPECT cameras. PET also produces less radiation exposure and is capable of performing quantitative measurements. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, leading to a 30% costs savings and excellent clinical outcomes compared to SPECT (M.E. Merhige, M.D., et al. Journal Nuclear Medicine 2007; 48: 1069-1076).  
The cardiac PET equipment market is much smaller than SPECT but has seen significant annual growth, of 25-30%, during the last decade. For many years, a major constraint for this market has been the high cost of PET and PET/CT scanners for cardiac studies. Positron has managed to reduce the buyers' barrier to entry by bringing to market the Attrius; the only cardiac dedicated PET system in the world. All other manufacturers (GE, Philips, Siemens) offer PET/CT systems that have a comparable performance of cardiac studies but have a 200% to 300% higher price, in relation to the Attrius. These same PET/CT systems also possess attributes not optimized or conducive for cardiac imaging. 

Attrius is the only FDA approved new dedicated PET scanner optimized for cardiac imaging.

The Attrius provides a robust, cardiac specific imaging software package designed to ensure effortless interpretation for today's most challenging clinical cases for nuclear cardiologists.  This innovative software includes coronary artery overlay display, open architecture for new protocol development, customization and motion correction and the ability to monitor therapy. The Attrius is targeted for cardiac clinics and hospitals and is designed to meet the performance, budget and space constraints of the most demanding cardiologists.
Attrius was named the "Most Innovative Device of 2010" by the renowned business research and consulting firm Frost & Sullivan.

Positron achieved significant advancements with the Company's new state-of-the-art coronary flow reserve (CFR) software, developed in collaboration with the University of Texas.
The CFR software, a clear differentiator for PET imaging compared to SPECT, was developed by a leading cardiologist and industry luminary Dr. K. Lance Gould and is considered to be a key driver in the upcoming growth in cardiac PET.

Positron is PET.

Company Website: http://www.positron.com

Share Structure
October 2017

Authorized Shares: 400,000,000 Common Shares
Outstanding Shares: 14,275,979  Common Shares (fully diluted)
Approximate Float: 4,000,000 Common Shares

Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

DISCLAIMER: The Moderator owns a position in POSC. He has not been compensated by any party for any post regarding POSC, and has never been compensated by any company nor any party for any post regarding any stock. Moderator may buy, hold, or sell his position at any time without warning to any party. Posts are not meant as a solicitation to buy, sell, or hold any position in POSC, nor any other stock. Moderator may be buying, or selling, stock in POSC as he is posting. There is no guarantee that the Moderator may not immediately eliminate his position on any day at any time during market hours. Do not buy, hold, or sell based upon any post regarding this stock, or any other equity. Do your own Due Diligence, and buy, sell, or hold based upon your own due diligence.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#19372   Most importantly for me will be sales Medtrade77 01/03/20 09:55:08 AM
#19371   There's a lot of tough history here for zenvesting 01/02/20 02:15:23 PM
#19370   PET was dead in water until now. I Medtrade77 01/02/20 01:02:31 PM
#19369   IMO addressing pharma was smart. No sales of Medtrade77 01/02/20 01:01:17 PM
#19368   Love is a strong word. I swallowed plinter1 01/02/20 10:23:13 AM
#19367   If you liked it in the past you Medtrade77 01/01/20 02:04:29 PM
#19366   Gave up plinter1 01/01/20 10:58:19 AM
#19365   Well it would be nice if posc could plinter1 01/01/20 10:57:18 AM
#19364   I would say some inexperienced investors/traders (perhaps doctors) zenvesting 12/30/19 03:11:26 PM
#19363   I heard they presented at an industry roundtable Medtrade77 12/30/19 10:36:29 AM
#19362   What is going on with this stock ? plinter1 12/30/19 09:59:56 AM
#19361   Nice move today, I expect this may move zenvesting 12/27/19 04:57:19 PM
#19360   A little actual buying at the ask the zenvesting 12/19/19 07:54:22 PM
#19359   “Demand for PET in 2020 will be highest Medtrade77 12/09/19 05:07:28 PM
#19358   Does anyone know who is a seller at Medtrade77 11/18/19 10:26:50 AM
#19357   I also hear the company wants to respect Medtrade77 11/12/19 01:43:25 PM
#19356   Anyone buying this should also be made aware zenvesting 11/12/19 01:33:11 PM
#19355   The market is too thin to use percentages Medtrade77 11/12/19 09:52:49 AM
#19354   Why? There's man reasons. The company is dark, zenvesting 11/11/19 03:53:34 PM
#19353   POSC why down 30%? swampboots 11/11/19 03:23:12 PM
#19352   End of tariffs Good news continues Medtrade77 11/07/19 11:56:16 AM
#19351   Great news, thanks for the update! zenvesting 11/06/19 01:34:06 PM
#19350   Positive future for cardiac PET. Just released 2020 Medicare Medtrade77 11/05/19 11:43:19 AM
#19349   Appreciate you’re knowledge of the industry. This is Medtrade77 10/22/19 10:40:43 AM
#19348   I understand there's lots of shareholders out there zenvesting 10/02/19 01:34:36 PM
#19347   I admire your faith with that amount of plinter1 10/02/19 12:32:19 PM
#19346   I accumulated a little more than 235,000 shares zenvesting 10/01/19 12:01:29 PM
#19345   At this level scoop up while some shares Medtrade77 08/01/19 02:40:40 PM
#19344   Well I withdrew my bid. 3 days at.16 plinter1 07/31/19 08:08:06 PM
#19343   I'm going to bid sit this tomorrow. See plinter1 07/16/19 02:57:48 PM
#19342   Any real shares for sale get purchased. It’s Medtrade77 07/15/19 10:07:46 AM
#19341   What do you make if the current trading? plinter1 07/13/19 03:57:19 PM
#19340   I understand it’s their systems superior capabilities in Medtrade77 07/08/19 10:21:38 AM
#19339   Other medical devices made in China fall under Medtrade77 07/08/19 10:14:08 AM
#19338   No no Insight here. The last time they plinter1 07/01/19 03:19:08 PM
#19337   I keep hearing about users needing Positron’s Attrius Medtrade77 06/18/19 03:02:35 PM
#19336   This means they are now compliant with SEC. Medtrade77 05/08/19 10:09:00 AM
#19335   So the latest registration does that mean they plinter1 05/04/19 02:02:37 PM
#19334   And apparently he's back 40,000 shares traded today plinter1 03/26/19 01:50:50 PM
#19333   There’s a buyer out there. Medtrade77 12/13/18 09:34:21 AM
#19332   Same here 2019 should be good. Couldn’t buy stock Medtrade77 12/10/18 06:10:39 PM
#19331   Most volume seen in a long time.....good news aapples1992 12/10/18 01:36:56 PM
#19330   Like what I see. Turn around looks underway. Medtrade77 12/10/18 11:24:30 AM
#19329   That is news from last month. Must take few Medtrade77 10/04/18 02:34:46 PM
#19328   I just checked the Ameritrade news for positron plinter1 10/04/18 10:03:48 AM
#19327   Agreed plinter1 09/11/18 01:52:08 PM
#19326   Of course I think the take away is Medtrade77 09/11/18 11:17:45 AM
#19325   Well good for them. I just wish they plinter1 09/11/18 08:38:50 AM
#19324   POSITRON ANNOUNCES SALE OF ATTRIUS PET SCANNER Niagara Medtrade77 09/10/18 08:03:02 AM
#19323   Thanks for the feedback and I will keep MTH4 08/14/18 06:13:14 PM